The benefits of such treatment are not limited to cancer, with evidence suggesting that regulating the immune response via the PD-1/PD-L1 interaction can also apply to infectious diseases such as tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis and malaria14–17. This evidence concerns the gene CD274 and cancer.